1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

21 Sep 2023
Admin
News Article

BeiGene Enter into Agreement with Novartis

BeiGene announced that it has entered into an agreement with Novartis to regain full control over the worldwide development, manufacturing, and commercialisation rights for TEVIMBRA (tislelizumab).

Under the terms of the agreement, Novartis will extend essential transition services and support to BeiGene. This collaborative effort will facilitate the seamless continuation of key components within the TEVIMBRA development and commercialisation plan.

These crucial aspects include manufacturing, regulatory affairs, safety protocols, and clinical support. In return, BeiGene has committed to supplying Novartis with a continuous clinical supply of TEVIMBRA to bolster its ongoing clinical trials.

Under the previous agreement, BeiGene and Novartis had a joint development effort for TEVIMBRA in various countries, including the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. In addition, Novartis will take on responsibility for regulatory submissions and commercialisation rights in these licenced regions once regulatory approval is obtained.

TEVIMBRA, an IgG4 anti-PD-1 monoclonal antibody, designed to minimise its interaction with Fc-gamma (Fcγ) receptors on macrophages. This strategic design aims to enhance the body's immune response against tumours by facilitating the detection and elimination of cancerous cells by immune cells.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!